公开(公告)号：US20130156794A1

公开(公告)日：2013-06-20

申请号：US13669194

申请日：2012-11-05

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Zelig ESHHAR ,  Assaf MARCUS ,  Tova WAKS

IPC: A61K35/14 ,  A61K31/4245 ,  A61K31/197 ,  A61K31/661 ,  A61K47/48 ,  A61N5/10 ,  A61K31/675 ,  A61K31/7076 ,  A61K31/185 ,  A61K31/196 ,  A61K39/395 ,  A61K31/135 ,  A61K48/00

CPC classification number: A61K35/17 ,  A61K31/135 ,  A61K31/137 ,  A61K31/185 ,  A61K31/196 ,  A61K31/197 ,  A61K31/4245 ,  A61K31/661 ,  A61K31/675 ,  A61K31/7076 ,  A61K39/39541 ,  A61K47/6891 ,  A61K48/00 ,  A61K2035/124 ,  A61N5/10 ,  B82Y5/00 ,  C07K16/32 ,  C07K2317/24 ,  C07K2317/622 ,  C07K2317/732 ,  C12N5/0636 ,  C12N5/0638 ,  C12N2501/2302 ,  C12N2501/50 ,  C12N2501/51 ,  C12N2501/515 ,  C12N2501/59 ,  C12N2501/599 ,  C12N2510/00

Abstract: A method of treating a disease, such as cancer, by administering to a subject in need of such treatment an effective amount of allogeneic T cells with a MHC unrestricted chimeric receptor short time after partial lymphodepletion. The method also comprises administering one or more agents that delay egression of the allogeneic T cells from lymph nodes of said subject during adoptive transfer of said allogeneic T cells to the subject by trapping the T cells in the lymph nodes.

Abstract translation: 通过向需要这种治疗的受试者施用有效量的具有MHC非限制性嵌合受体的部分淋巴结清除后短时间的有效量的同种异体T细胞来治疗疾病如癌症的方法。 所述方法还包括在将所述同种异体T细胞过继转移给受试者之前通过将T细胞捕获在淋巴结中来施用一种或多种在同种异体T细胞从所述受试者的淋巴结中释出出血的药剂。

公开(公告)号：US20170216356A1

公开(公告)日：2017-08-03

申请号：US15432534

申请日：2017-02-14

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： Zelig ESHHAR ,  Assaf MARCUS ,  Tova WAKS

IPC: A61K35/17 ,  C12N5/0783 ,  A61K31/137 ,  C07K16/32 ,  A61K31/675

CPC classification number: A61K35/17 ,  A61K31/135 ,  A61K31/137 ,  A61K31/185 ,  A61K31/196 ,  A61K31/197 ,  A61K31/4245 ,  A61K31/661 ,  A61K31/675 ,  A61K31/7076 ,  A61K39/39541 ,  A61K47/6891 ,  A61K48/00 ,  A61K2035/124 ,  A61N5/10 ,  B82Y5/00 ,  C07K16/32 ,  C07K2317/24 ,  C07K2317/622 ,  C07K2317/732 ,  C12N5/0636 ,  C12N5/0638 ,  C12N2501/2302 ,  C12N2501/50 ,  C12N2501/51 ,  C12N2501/515 ,  C12N2501/59 ,  C12N2501/599 ,  C12N2510/00

Abstract: A method of treating a disease, such as cancer, by administering to a subject in need of such treatment an effective amount of allogeneic T cells with a MHC unrestricted chimeric receptor short time after partial lymphodepletion. The method also comprises administering one or more agents that delay egression of the allogeneic T cells from lymph nodes of said subject during adoptive transfer of said allogeneic T cells to the subject by trapping the T cells in the lymph nodes.